The cardiovascular risk carried by psoriasis has long been attributed to shared inflammatory pathways and comorbidities like obesity and diabetes — but a large new echocardiographic study suggests the heart may bear a direct burden from psoriatic disease itself, one that persists even when skin symptoms are well controlled. That distinction matters enormously for the tens of millions of adults worldwide living with psoriasis who assume effective dermatological treatment translates into reduced cardiac risk.
The PSOCADIA cohort enrolled 1,010 adults with psoriasis and matched them 1:1 to controls by age and sex. All participants underwent transthoracic echocardiography, with myocardial dysfunction defined by global longitudinal strain (GLS) below 16% — a sensitive, subclinical marker of left ventricular function that detects impairment before ejection fraction declines. The key finding: 16.7% of psoriasis patients met criteria for myocardial dysfunction versus just 6.0% of controls — nearly a threefold difference. Critically, this association held after statistical adjustment for cardiometabolic risk factors and established atherosclerotic cardiovascular disease. Notably, dysfunction prevalence did not escalate with greater psoriasis severity, suggesting the effect is not simply dose-dependent inflammation.
This finding challenges the prevailing model in which psoriasis-associated cardiac risk is largely mediated through downstream comorbidities. The persistence of abnormal GLS after covariate adjustment points toward a more intrinsic mechanism — possibly chronic low-grade systemic inflammation, immune-mediated myocardial remodeling, or microvascular dysfunction independent of macrovascular atherosclerosis. GLS is increasingly recognized as a clinically meaningful predictor of future heart failure and adverse cardiac events, giving these subclinical findings real prognostic weight. The cross-sectional design limits causal inference, and it remains unknown whether psoriasis treatment modifies GLS over time — a gap prospective PSOCADIA follow-up data may eventually address. For a dermatology-managed population, these findings make a compelling case for systematic cardiac surveillance beyond conventional risk scoring.